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Striated muscleAlthough it is well known that insulin controls the synthesis of glycogen from non-carbohydrates by
down-regulating expression of several glyconeogenic enzymes, a mechanism of short-term inhibition of
glyconeogenesis remains unknown. In recent years, we have shown that in skeletal muscle, fructose
1,6-bisphosphatase (FBPase) is a part of the hypothetical glyconeogenic complex located on sarcomeric
Z-line. Here, we show that inhibition of glycogen synthase kinase-3 causes disruption of the FBPase–Z-line
interactions and reduction of muscle glycogen content in vivo. The normal, striated pattern of muscle FBPase
localization is also disturbed by insulin treatment but preserved when insulin is applied together with Akt
inhibitor. We suggest that destabilization of FBPase–Z-line interaction is a universal cellular mechanism of
glyconeogenesis down-regulation, allowing for preferential utilization of glucose for insulin-stimulated mus-
cle glycogen synthesis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Insulin stimulates the rate of glycolysis as well as the uptake of glu-
cose and its conversion into glycogen— a process called glycogenesis. At
the same time, insulin inhibits glyconeogenesis, the synthesis of glyco-
gen from non-carbohydrates. Although these effects of insulin were in-
tensively studied and it is well known that the hormone down-
regulates expression of several glyconeogenic enzymes, a mechanism
of a fast short-term inhibition of glyconeogenesis remains unknown.
Fructose 1,6-bisphosphatase (FBPase; EC 3.1.3.11) is an ancient evo-
lutionary enzyme which regulates the synthesis of glucose/glycogen
from non-carbohydrates. The muscle FBPase isozyme is expressed in
all vertebrate cells. In muscle tissue, together with aldolase and likely
other glyconeogenic enzymes, FBPase forms a dynamic multi-enzyme
complex in a region of the sarcomeric Z-line [1,2], the region in which
glycogen synthase has also been localized [3]. Such complex, regulated
by physiological state of the cell, is presumed to be indispensable for
glyconeogenesis in vertebrates [4].
Muscle FBPase gained our attention as a potential multi-functional
protein, engaged not only in regulation of glyconeogenesis but also cell
division and mortality [5–7]. We have shown that in cardiomyocytes,
nuclear transport of FBPase requires phosphorylation of the enzyme by
PKA. However, the relatively slow rate of PKA activity-stimulated FBPase
translocation suggested that an additionalmodiﬁcation of FBPase is nec-
essary for its nuclear presence [7]. Quite recently,we have demonstrated+48 71 375 92 13.
l rights reserved.evidence that muscle FBPase could be a target of glycogen synthase
kinase-3 (GSK3) — a key element of glycogen biosynthesis and a con-
troller of apoptosis or necrosis. We have found that inhibition of GSK3
reduced the amount of nuclear FBPase in HL-1 cardiomyocytes [8].
Moreover, inhibition of the kinase also induced translocation of FBPase
to mitochondria, resulting in an in vitro reduction of their sensitivity to
calcium-induced swelling and affecting ATP synthesis.
Based on in vitro data we have suggested that FBPase is involved
in a regulation of cell survival by interaction with mitochondrial pro-
teins which control the energy homeostasis [8].
Inhibition ofGSK3 is a part of the insulin-stimulated signaling process
and muscle FBPase might be a substrate of GSK3. Therefore we focused
our attention on effects of the kinase inhibition on glyconeogenesis
and localization of FBPase in striated muscles.
In the present paper, we show for the ﬁrst time that muscle FBPase
is a target of the GSK3 pathway in vivo and a substrate of the kinase in
vitro. Using zebraﬁsh and rat as animal models, we demonstrate that
inhibition of GSK3 causes disruption of the FBPase–Z-line interaction
and reduction in muscle glycogen content. The striated pattern of
muscle FBPase localization is also disturbed by insulin but preserved
when insulin is applied together with Akt inhibitor.
Based on these resultswe propose that in vertebrate skeletalmuscle,
inhibition of GSK3 reduces the rate of glyconeogenesis destabilizing the
glyconeogenic complex bypromotion of the detachment of FBPase from
the Z-line. We suggest that this is a universal cellular mechanism of
glyconeogenesis inhibition in vertebrates, allowing for preferential uti-
lization of glucose for insulin-stimulated muscle glycogen synthesis.
Additionally, we present the ﬁrst in vivo evidence that inhibition
of GSK3 results in FBPase interaction with mitochondria.
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2.1. Chemicals
Glycogen Assay Kit was obtained from Abcam (UK), rabbit poly-
clonal anti-cytochrome c antibody (catalog no. ABIN222880) from
BioVision (USA), polyester wax from Electron Microscopy Sciences
(USA), Fluorescent Mounting Medium was from Dako (Denmark)
and QuikChange® Lightning Site-Directed Mutagenesis Kit was from
Agilent Technologies. Akt IV inhibitor was purchased from Santa
Cruz Biotechnology. PageRuler™ Prestained Protein Ladder was
from Thermo Scientiﬁc. All other reagents were purchased from
Sigma-Aldrich (USA).
2.1.1. Animals
Wild-type zebraﬁsh were obtained from a specialized supplier
(Zebraﬁsh International Resource Center, USA). The ﬁsh were kept
in a 60-l aquarium with controlled water quality at 28, and at
14 h day/10 h night cycle. They were fed ad libitum twice daily with
commercial ﬂakes. In the experiments, ﬁsh from the same hatch were
used.
Male Wistar rats were obtained from the Department of Patholog-
ical Anatomy, Wroclaw Medical University.
2.2. In vitro assay
Adult (8-month-old) ﬁsh were euthanized with 0.02% tricaine
methanesulphonate, in agreement with the rules of The Scientiﬁc Re-
search Ethical Committee. Immediately dissected myotomal skeletal
muscles were immersed for 15 min at 28 °C in a glutamine-
supplemented L-15 medium with addition of GSK3 inhibitors:
20 mM LiCl or 2 μM SB216763 dissolved in DMSO [9]. As a control,
the tissue samples were incubated in the medium supplemented
with 20 mM NaCl instead of LiCl or with DMSO. The concentration
of DMSO did not exceed 0.02%. In another set of experiments, muscle
tissue samples were incubated in the above conditions but the medi-
umwas supplemented with 0.1 μM of bovine insulin and 1 μMAkt ki-
nase inhibitor or with 0.1 μM insulin alone.
After treatment, the samples were ﬁxed and used for immunohis-
tochemistry and Periodic Acid-Schiff (PAS) staining.
Adult (3-month-old) rats were euthanized by decapitation, in
agreement with the rules of The Scientiﬁc Research Ethical Commit-
tee. Immediately dissected gastrocnemius muscle samples were im-
mersed in glucose-free or glucose-supplemented DMEM with or
without addition of 2 μM SB216763 for 30 min at 37 °C. After treat-
ment, the samples were used in the glycogen assay and immunohis-
tochemical experiments.
2.3. In vivo assay
Adult ﬁsh, free of signs of any disease were placed in 1-l beakers
and exposed to water supplemented with 100 mM LiCl or 10 μM
SB216763 [10,11] for 45 min. Control ﬁsh were kept in water
supplemented with respective amount of NaCl or DMSO. The concen-
tration of DMSO in the water did not exceed 0.02%. The ﬁsh were
monitored and showed no signs of stress (e.g. difﬁculties with swim-
ming, excessive gill movement). After the treatment, the ﬁsh were
euthanized as described above (Section 2.2 In vitro assay). Skeletal
muscles were immediately dissected and used in the glycogen
assay, PAS staining and immunohistochemical experiments.
2.4. Glycogen assay
Preparation of samples and themeasurement of glycogen level were
performed with the Glycogen Assay Kit, following the procedure sup-
plied by the manufacturer. Brieﬂy, ﬁsh were treated as describedabove and their skeletal muscles were homogenized on ice and boiled
for 5 min to inactivate enzymes. After centrifugation (15 700 g for
5 min), obtained supernatants were used for the colorimetric assay,
which comprised hydrolysis of glycogen, oxidization of the resultant
glucose and incubation with OxiRed probe to generate color product.
The product of the oxidization was detected with the Asys Biochrom
UVM340 plate reader at 570 nm. To determine the glucose background
in samples, the assay was performed without addition of glycogen hy-
drolysis enzyme. The background readings were then subtracted from
the respective sample readings. Glycogen concentrations in the samples
were calculated using the standard curve.
Alternatively, the glycogen level was measured in rat gastrocne-
mius muscle samples, treated as described above (Section 2.2 In
vitro assay).
2.5. Glycogen staining
Muscle tissue was ﬁxed in Gendre's ﬁxative and embedded in poly-
ester wax. 5 μm sections were cut from the tissue blocks. The sections
were de-waxed and stained with Periodic Acid-Schiff Staining Kit
(Sigma-Aldrich) and counterstained with hematoxylin following the
standard procedure supplied by the manufacturer. In the experiment,
duplicate test slides were used: one for glycogen digestion with
α-amylase before the PAS staining (control slide) and one for the PAS
staining only. PAS-positive substances stain dark pink to purple. The
α-amylase-treated slides have no visible staining of glycogen, com-
pared to the undigested slides.
2.6. Immunohistochemistry
The antibodies against mouse muscle FBPase were produced, puri-
ﬁed and tested as we described before (for example see [8]).
Sections of 5 μm of skeletal muscle tissue were incubated with
polyclonal anti-muscle FBPase primary antibody (1:400) and with
anti-cytochrome c antibody (2 μg/ml). These antibodies were then
detected with FITC-conjugated or Alexa 633-conjugated secondary
antibodies, respectively. In control reactions, the primary antibodies
were omitted. The tissue sections were embedded in Fluorescent
Mounting Medium and examined with the FluoView 1000 confocal
microscope (Olympus).
2.7. Western blot
To determine if there is any difference in electrophoretic mobility
between cytosolic (i.e. not bound to subcellular structures) and total
cellular FBPase a Western blot was performed.
To prepare the cytosolic proteins extract from rat skeletal muscle,
freshly dissected samples of the tissue were mildly homogenized
with Ultra Turrax T8 homogenizer (IKA Labortechnik) in an ice-cold
buffer: 20 mM TRIS, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 60 mM
NaF, 1 mM PMSF, 1 μg/ml leupeptin, pH 7.4, 4 °C and centrifuged
for 20 min at 20 000 g. To prepare the total protein extract from the
skeletal muscle, the fresh samples of rat muscle were homogenized
in 100 mM TRIS, 2% SDS and 100 mM DTT, pH 8.0, boiled for 5 min
and centrifuged as described above.
The extracts (100 μg) were resolved by 10% SDS-PAGE and
transferred to the polyvinyl diﬂuoride blotting membrane and FBPase
was detected with the anti-muscle FBPase antibodies and secondary
antibodies conjugated with peroxidase. As a peroxidase substrate,
3,3′-diaminobenzidine was used.
2.8. Site-directed mutagenesis and protein isolation
The NetPhosK predictions led to the identiﬁcation of numerous
potential phosphorylation sites for glycogen synthase kinase-3 within
the muscle FBPase structure. However, among these sites serine 320
624 A. Gizak et al. / Biochimica et Biophysica Acta 1833 (2013) 622–628is the only residue located on the surface of FBPase. Thus this residue
is a potential candidate for a target of the kinase.
Site-directed mutagenesis of the human muscle FBPase was
performed using the pHMF2 plasmid [12] as a template and the
QuikChange® Lightning Site-Directed Mutagenesis Kit, according to
the protocol provided by the manufacturer. The mutagenic primers
were as follows (mutation underlined): Ser320Ala forward: 5′-CCCCT
CATTCTGGGGGCACCAGAGGATGTGCAG-3′ and Ser320Ala reverse:
5′-CTGCACATCC TCTGGTGCCCCCAGAATGAGGGG-3′. The mutation
was conﬁrmed by commercial DNA sequencing. FBPase expression
and puriﬁcation were performed as described previously [1]. Protein
purity and concentration throughout the puriﬁcation procedure
were monitored, respectively, by SDS-PAGE and Bradford assay.
2.9. In vitro phosphorylation assay
5 μg of the wild-type human muscle FBPase and its mutant
(Ser320Ala) were phosphorylated with 4 units of human GSK3β for
1 h at 30 °C, pH 7.0. The reaction was performed in the presence of
25 mM Tris-HCl, 10 mM MgCl2, 100 mM KCl, 100 μM ATP (2 μCi of
[γ-32P]ATP), 1 mM DTT, pH 7.0 for 1 h at 30 °C, and was terminated
by the addition of a 4× SDS (sodium dodecyl sulfate) sample buffer.
The samples were denatured at 95 °C for 10 min, prior to protein
separation by SDS-PAGE.
The resultant gel was stained with Coomassie Brilliant Blue to ver-
ify the presence of FBPase. Then the gel was dried in a vacuum at
80 °C and exposed to Imaging Plates (Fuji Photo Film). Fluorescence
signal was scanned with the Fuji Film FLA-3000 Fluorescent Image
Analyzer (Raytest Isotopenmeßgerate GmbH).
2.10. Statistical analysis
Collected data was analyzed using the Microsoft Excel 2000 and
SISA software (Simple Interactive Statistical Analysis — http://www.
quantitativeskills.com/sisa). Results are expressed as mean and stan-
dard deviation (S.D.). For an evaluation of statistical signiﬁcance the
Student's t-test was used. A probability of pb0.05 was considered to
represent a signiﬁcant difference.Fig. 1. Immunolocalization of FBPase in zebraﬁsh skeletal muscle. (A) Localization of the en
inhibitors: 20 mM LiCl (B) or 2 μM SB216763 (C), and (D) after incubation with 20 mM NaC
(F) on FBPase localization in muscle. Bar=5 μm.3. Results
3.1. In vitro experiments
Immunohistochemical experiment performed on the wax sections
of skeletal muscle with the use of anti-muscle FBPase antibodies re-
vealed that in control conditions, Danio rerio muscle FBPase, as in
other vertebrates [1,4], locates on sarcomeric Z-lines (Fig. 1A). How-
ever, if the muscle tissue samples were treated with GSK3 inhibitor
(20 mM LiCl or 2 μM SB216763) prior to ﬁxation, the striated pattern
of FBPase localization was not observed (Fig. 1B–C). Pre-treatment of
the muscle samples with 20 mM NaCl (Fig. 1D) or DMSO (data not
shown) did not disturb the FBPase–Z-line interactions.
For visualization of glycogen content, the PAS staining was
performed. The control (NaCl- or DMSO-treated) muscle tissue sec-
tions were stained dark pink (Fig. 2A). The staining of GSK3
inhibitor-treated sections was visibly weaker (Fig. 2B), similar to
the “negative control”, in which the glycogen deposits were removed
from the control muscle tissue sections with α-amylase digestion
prior to PAS staining (Fig. 2C).
To test if the observed change of FBPase distribution could be in-
duced by activation of insulin signaling pathway, subcellular localiza-
tion of the enzyme was examined in skeletal muscle samples treated
with insulin alone or together with inhibitor of Akt kinase. Akt is a
downstream target of insulin and inhibition of the kinase blocks
transmission of signals from insulin to GSK3.
As it is demonstrated in Fig. 1E, in the presence of insulin, the stri-
ated pattern of FBPase localization was substituted with a dispersed
cytosolic distribution of the enzyme. However, in the presence of
both insulin and Akt kinase inhibitor, the Z-line-based location of
FBPase remained unchanged (Fig. 1F).
3.2. In vivo experiments
In skeletal muscle of zebraﬁsh treated with GSK3 inhibitors in vivo,
the same change of FBPase localization was observed (Fig. 3A–B) as in
the in vitro experiments. Additionally, a careful screening of the tissue
sections revealed co-localization of the enzyme with mitochondriazyme in untreated muscle, (B–C) after in vitro incubation of skeletal muscle with GSK3
l. (E–F) The effect of application of insulin alone (E) or in the presence of Akt inhibitor
Fig. 2. The glycogen content in zebraﬁsh skeletal muscle. (A–C) PAS staining: control conditions— untreated muscle (A); muscle incubated in vitro with GSK3 inhibitor— SB216763
(B); muscle treated with α-amylase prior to PAS staining (C). Bar=10 μm. (D) Glycogen content in zebraﬁsh skeletal muscle, measured with the Glycogen Assay Kit, after in vivo
exposition of the ﬁsh to GSK3 inhibitors. Each value represents the mean and S.D. of at least 6 individual measurements; pb0.005.
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mitochondria were located within the myoﬁbrils, in a typical, regular
fashion and position of these organella did not overlap with FBPase lo-
calization (Fig. 3A). However, GSK inhibition changed the pattern ofmi-
tochondria to a bit less regular (Fig. 3D–E) and resulted in translocation
of FBPase to the organella (Fig. 3C,E).
The PAS staining-based comparison of muscle glycogen content
between the control and the GSK3 inhibitor-treated ﬁsh revealed dif-
ferences in the polysaccharide amount, in favor of the control animal
(data not shown). To verify these histochemical results, glycogen
level was measured in homogenates of zebraﬁsh skeletal muscle tis-
sue, with the use of microplate reader and Glycogen Assay Kit. As it
is presented in Fig. 2D, in vivo treatment of zebraﬁsh with lithium
and SB216763 resulted in, respectively, about 2- and 1.6-fold de-
crease in muscle glycogen content.
The inhibitor-type dependent differences in glycogen reduction
were statistically signiﬁcant and they probably stem from distinct
mode of their action. SB216763 is a highly speciﬁc GSK3 inhibitor
[9]. Lithium, besides being a Mg-competitive inhibitor of the enzyme,
inhibits also protein phosphatases [13]. Since dephosphorylation is a
key step in activation of glycogen synthase, one might expected that
lower activity of phosphatases would result in lower activity of the
synthase.Fig. 3. The visualization of FBPase (green) and cytochrome c (red) in skeletal muscle after i
Staining of FBPase and mitochondria practically does not overlap. (B–E) Skeletal muscle of
co-localization of FBPase and mitochondrial staining is observed (C–E). Bar=5 μm.3.3. FBPase localization and glycogen content in rat muscle
To determine if the changes observed in zebraﬁsh constitute a uni-
versal phenomenon we checked the subcellular localization of FBPase
and assayed the glycogen content in isolated rat gastrocnemius
muscle samples treated in vitro with 2 μM SB216763. As it is demon-
strated in Fig. 4, in the presence of the GSK3 inhibitor, FBPase
appeared to be evenly dispersed in cytosol. This was correlated with
about 1.4-fold decrease in muscle glycogen content (Fig. 4C), despite
the presence of gluconeogenic substrates in the incubation medium.
However, if the muscle was incubated with SB216763 in the presence
of 5.5 mM glucose in medium, despite disrupted FBPase–Z-line inter-
actions the measured glycogen amount in the GSK3 inhibitor-treated
muscle did not differ signiﬁcantly from the control samples (Fig. 4C).
3.4. Western blot
When Western blot was probed with anti-muscle FBPase anti-
bodies we observed only one band of approximately 37 kDa in the
cytosolic proteins extracted from rat skeletal muscle.
In the total muscle proteins extract, we observed two closely mi-
grating bands (Fig. 5) which might reﬂect the unmodiﬁed – cytosolic,
and phosphorylated – sarcomere-bound, FBPase.n vivo exposition of zebraﬁsh to GSK3 inhibitors. (A) Skeletal muscle of untreated ﬁsh.
ﬁsh treated with the inhibitors: LiCl (B) or SB216763 (C–E). After inhibition of GSK3,
Fig. 4. Changes of FBPase localization and glycogen content in GSK3 inhibitor-treated rat skeletal muscle. (A) Localization of FBPase in untreated muscle and (B) after in vitro in-
cubation of the muscle with 2 μM SB216763. (C) Glycogen content in white rat skeletal muscle measured with the Glycogen Assay Kit. Each value represents the mean and S.D. of at
least 6 individual measurements; *pb0.005.
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The in vitro phosphorylation of FBPase by GSK3β resulted in the
incorporation of the 32P-labeled phosphate group onto the hydroxyl
group of Ser and/or Thr residues of FBPase, as it was visualized by au-
toradiography (Fig. 6). The autoradiogram showed that GSK3β phos-
phorylated the wild-type human muscle FBPase (Fig. 6A,C), but not
the Ser320Ala mutant (Fig. 6B,D), which indicates that Ser320 was
the residue phosphorylated by GSK3 in vitro. No signal was observed
in the control experiment, carried out in the absence of the kinase,
[γ-32P]ATP or FBPase (data not shown).Fig. 5. Immunodetection of FBPase in rat skeletal muscle extracts. Lane A: cytosolic prot
sarcomere-bound) muscle proteins.
Fig. 6. In vitro phosphorylation of FBPase by GSK3β. (A,B) The autoradiogram visualizing ra
mutant (B). Position of FBPase is marked with arrowhead. Arrow marks the position of aut
muscle FBPase (C) and Ser320Ala mutant (D).4. Discussion
Glycogen synthase kinase-3 is amulti-functional kinase and a crucial
element of a broad range of cellular processes, including differentiation
and apoptotic or necrotic death (for review see [14]). However, origi-
nally it has been identiﬁed as a regulator of cellular amount of glycogen
by phosphorylation and thus inhibition of glycogen synthase — a
rate-limiting enzyme of glycogen biosynthesis [15].
GSK3 is a constitutively active kinase but it is inhibited by the in-
sulin signaling pathway. The hormone exerts its regulatory effect on
GSK3 indirectly, through activation of protein kinase B (PKB)/Akteins; lane B: molecular mass markers (40 and 35 kDa); lane C: total (cytosolic and
dioactivity from phosphate groups incorporated in wild-type FBPase (A) and Ser320Ala
ophosphorylated GSK3β. (C,D) Coomassie dye-staining of gels visualizes the wild-type
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phatase 1. As an effect, glycogen synthase activity is up-regulated.
Since at the same time insulin stimulates glucose uptake into muscle
ﬁbers, glycogen content in skeletal muscles increases [17].
Muscle FBPase, a key enzyme of glyconeogenesis, appears to be an
essential part of the glyconeogenic complex located in a region of the
sarcomeric Z-line, where the enzyme interacts with muscle aldolase
and α-actinin [1,2]. The unbound, cytosolic muscle FBPase is almost
completely inactive. However, the interaction with aldolase desensi-
tizes muscle FBPase to its physiological inhibitors: AMP and calcium,
and results in the intermediate channeling between the two enzymes
[18]. Formation of the Z-line-based glyconeogenic complex is also
presumed to lead to compartmentalization and thus separation of
glycolytic and glyconeogenic pathways in order to prevent muscle
ﬁbers from dissipating energy via futile cycle [2].
In the present work, we demonstrate the ﬁrst in vivo evidence that
in an animal model, muscle FBPase is an element of the GSK3 pathway.
Exposition of zebraﬁsh to GSK3 inhibitors, which mimics the activation
of insulin receptor, results in detachment of FBPase from the Z-line.
Simultaneously, a signiﬁcant reduction in glycogen content in muscle
ﬁbers is observed. Because free, cytosolic FBPase is inactive, it is evident
that the GSK3 inhibition-induced changes in the FBPase–Z-line interac-
tions limit glycogen synthesis from non-carbohydrates.
Since ﬁsh were fed at libitum, these results also indicate that in
zebraﬁsh muscle, a considerable amount of glycogen is synthesized
from non-carbohydrate sources, even in conditionswhich are not relat-
ed to the recovery from high-intensity work. It is in line with the work
of West et al. [19] showing that in skeletal muscles of trout, glucose
accounted for less than 15% of glycogen repletion and suggesting that
in teleost ﬁsh, glucose metabolism is involved largely with mucus
production.
In mammalian skeletal muscle, the insulin- and GSK3 inhibitor-
induced glycogen synthesis proceeds mainly from glucose, not from
non-carbohydrate sources [9,20–22].
In line with this, we found that in the presence of glucose, glyco-
gen amount in the GSK3 inhibitor-treated rat skeletal muscle did
not differ signiﬁcantly from the amount in control samples, although
the interaction of FBPase with the Z-line was disrupted.
However, if the muscle was treated with the GSK3 inhibitor in the
absence of glucose, dissociation of FBPase from the Z-line was correlat-
ed, as in Danio, with the decrease in muscle glycogen content, despite
the presence of gluconeogenic substrates in the incubation medium.
Compatibility of the GSK3 inhibition effects observed in rat and
zebraﬁsh suggests that this is a universal phenomenon. This also sug-
gests that in the condition of low blood glucose and thus in the absence
of GSK3-inhibiting insulin, mammalian striated muscles replenish their
glycogen from endogenous sources. It is in agreement with the ﬁndings
of Fournier et al. [23], showing that in mammals, up to 50% of muscle
glycogenmay be re-synthesized from non-carbohydrates during recov-
ery from a high-intensity physical activity.
In striated muscle, high [Ca2+] affecting the association of glyco-
lytic and glyconeogenic enzymes to sarcomeric structures is a recip-
rocal regulator of glyconeogenesis and glycolysis during exercise
[24]. However, insulin stimulates glucose uptake, glycolysis and gly-
cogenesis in a calcium-independent manner. Results of our present
study demonstrate that the insulin-mediated GSK3 inhibition desta-
bilizes the FBPase–Z-line interaction. Therefore, we suggest that the
dissociation of FBPase from the sarcomeric structures under GSK3 in-
hibition is the primary, fast mechanism of glyconeogenesis down-
regulation in conditions of high blood glucose and a consequent
high insulin level.
This assumption is strengthened by the observation that in the
insulin-treated zebraﬁsh skeletal muscle, the control, striated pattern
of FBPase distribution disappears. However, if the signaling from in-
sulin to GSK3 is disrupted by inhibition of Akt, the control localization
of FBPase remains unchanged.One of the conclusions of our study is that the Z-line-associated
FBPase should bemodiﬁed by GSK3 or by one of its down-stream target
enzyme. We found that in the fraction of rat muscle cytosolic proteins
subjected to Western blotting, only one band could be detected with
the anti-FBPase antibodies, whereas in the fraction of total muscle pro-
teins, two closely migrating bands could be detected which might re-
ﬂect the unmodiﬁed – cytosolic, and phosphorylated – sarcomere-
bound FBPase. Additionally, we found that GSK3 phosphorylates serine
320 of muscle FBPase in vitro. However, the level of such phosphoryla-
tion is low. Thus, it might be expected that FBPase needs either a prim-
ing phosphorylation by another kinase, or a cellular binding partner
(e.g. aldolase) to be a substrate for GSK3.
A few years ago, we proposed a calcium-dependent mechanism of
glyconeogenic complex destruction and glycogen synthesis inhibition
in skeletal muscle [24]. Changes in free cytosolic Ca2+ concentration
are one of the main regulatory mechanisms controlling energy pro-
duction for the muscle contraction. Elevated calciummodulates activ-
ity of numerous enzymes, among them those involved in glycogen
mobilization (e.g. glycogen phosphorylase) [25]. At the same time,
Ca2+-dependent kinases phosphorylate and thus inactivate glycogen
synthase [26], and Ca2+ concentrations characteristic for contracting
muscle disrupt FBPase interaction with aldolase and α-actinin of the
Z-line [4,24].
Therefore, considering our previous and present results, it could be
concluded that dissociation of FBPase from the Z-line is a universal cel-
lular mechanism of glyconeogenesis inhibition. These results also dem-
onstrate that the formation of macromolecular enzymatic complexes is
indispensable for efﬁcient progression of metabolic processes in a cell.
Quite recently, evidence has come into light that muscle FBPase
has a much broader functional repertoire than participation in glyco-
gen synthesis. In our previous papers, based mostly on in vitro results,
we have suggested that in vertebrates, the GSK3 inhibition- and high
calcium-stimulated association of muscle FBPase with mitochondria
might be a mechanism adapting skeletal and cardiac muscle to
Ca2+-overload during prolonged high-intensity exercise training,
without progression to heart failure and death [4,8].
Presented here results demonstrate that the exposition of
zebraﬁsh to the GSK3 inhibitors leads not only to detachment of
FBPase from the Z-line, but also to translocation of the enzyme to mi-
tochondria in vivo. It has been demonstrated that in heart, high glu-
cose level resulting in intensive glycolysis and a subsequent high
activity of electron transport chain, is the cause of reactive oxygen
species overproduction in mitochondria [27]. Therefore, it might be
speculated that GSK3 inhibition-mediated binding of FBPase to mito-
chondria protects the organella not only from the high calcium- but
also high glucose-induced stress.
5. Conclusions
We propose that the detachment of FBPase from the Z-line is a
universal cellular mechanism of a fast short-term inhibition of
glyconeogenesis in vertebrates, allowing for preferential utilization
of glucose to insulin-stimulated muscle glycogen synthesis. The role
of mitochondrial translocation of FBPase in these conditions remains
unclear, but is currently under research.
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